» Articles » PMID: 33367194

Course and Predictive Factors of Incomplete Response to Therapy in Low- and Intermediate-Risk Thyroid Cancer

Overview
Journal J Endocr Soc
Specialty Endocrinology
Date 2020 Dec 28
PMID 33367194
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Controversy surrounds the extent and intensity of the management of American Thyroid Association (ATA) intermediate- and low-risk patients with differentiated thyroid cancer (DTC). Understanding the natural history and factors that predict outcome is important for properly tailoring the management of these patients.

Objective: This work aims to study the natural course and predictive factors of incomplete response to therapy in low- and intermediate-risk DTC.

Patients And Methods: We studied a cohort of 506 consecutive patients [418 women (82.6%) and 88 men (17.4%)] with low and intermediate risk with a median age of 35 years (interquartile range [IQR], 27-46 years). We analyzed the natural course and the predictive factors of biochemically or structurally incomplete response.

Results: Of 506 patients studied, 297 (58.7%) patients were in the low-risk group and 209 (41.3%) were in the intermediate-risk group. Over a median follow-up of 102 months (IQR, 66-130 months), 458 (90.5%) patients achieved an excellent response, 17 (3.4%) had a biochemically incomplete status, and 31 (6.1%) had a structurally incomplete status. In univariable and multivariable analyses, age (≥ 33 years) ( < .0001, odds ratio 1.06 [1.04-1.08]) and lateral lymph node metastasis (LNM;  < .0001, odds ratio 3.2 [1.7-5.9]) were strong predictive factors for biochemically and structurally incomplete response to therapy. Sex, tumor size, multifocality, extrathyroidal extension, and lymphovascular invasion did not predict incomplete response to therapy.

Conclusions: Patients with low- and intermediate-risk DTC have favorable outcomes. Age and lateral LNM are strong predictors of an incomplete response to therapy. This suggests that older patients and those with LNM should be managed and followed up more actively than younger patients and those without LNM.

Citing Articles

Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma.

Keshavarzi A, Alaei-Shahmiri F, Fallahi B, Emami Z, Malek M, Khamseh M BMC Endocr Disord. 2024; 24(1):112.

PMID: 39004697 PMC: 11247765. DOI: 10.1186/s12902-024-01648-8.


Course and predictors of excellent response to therapy in patients with differentiated thyroid cancer at long-term follow-up.

Samargandy S, Qorban G, Aljadani A, Almufarji S, Azab A, Merdad M Saudi Med J. 2024; 45(2):139-146.

PMID: 38309729 PMC: 11115420. DOI: 10.15537/smj.2024.45.2.20230596.


The American Thyroid Association risk stratification and long-term outcomes of differentiated thyroid cancer: a 20-year follow-up of patients in Saudi Arabia.

Jammah A, AlSadhan I, Alyusuf E, Alajmi M, Alhamoudi A, Al-Sofiani M Front Endocrinol (Lausanne). 2023; 14:1256232.

PMID: 38047113 PMC: 10690932. DOI: 10.3389/fendo.2023.1256232.


Application of the American Thyroid Association Risk Assessment in Patients with Differentiated Thyroid Carcinoma in a German Population.

Eilsberger F, Kreissl M, Reiners C, Holzgreve A, Luster M, Pfestroff A Biomedicines. 2023; 11(3).

PMID: 36979890 PMC: 10045624. DOI: 10.3390/biomedicines11030911.


Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer.

Gao H, Huang J, Dai Q, Su J Arch Endocrinol Metab. 2023; 67(2):197-205.

PMID: 36651706 PMC: 10689029. DOI: 10.20945/2359-3997000000538.


References
1.
Kelly A, Barres B, Kwiatkowski F, Batisse-Lignier M, Aubert B, Valla C . Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients. PLoS One. 2019; 14(8):e0221298. PMC: 6699685. DOI: 10.1371/journal.pone.0221298. View

2.
Byar D, Green S, DOR P, Williams E, Colon J, VAN GILSE H . A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer (1965). 1979; 15(8):1033-41. DOI: 10.1016/0014-2964(79)90291-3. View

3.
Tuttle R, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M . Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid.... Thyroid. 2010; 20(12):1341-9. PMC: 4845674. DOI: 10.1089/thy.2010.0178. View

4.
Hay I, Bergstralh E, Goellner J, Ebersold J, Grant C . Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993; 114(6):1050-7; discussion 1057-8. View

5.
Stulak J, Grant C, Farley D, Thompson G, van Heerden J, Hay I . Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006; 141(5):489-94. DOI: 10.1001/archsurg.141.5.489. View